EMA committee recommends approvals for Lilly’s weight loss drug, Mirati’s KRAS inhibitor and more

The Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) this week gave a thumbs-up to nine la­bel ex­pan­sions and eight new drugs, in­clud­ing Eli Lil­ly’s tirzepatide in weight man­age­ment and Mi­rati’s Kraza­ti in non-small cell lung can­cer pa­tients.

The pos­i­tive rec­om­men­da­tion for tirzepatide came down Thurs­day, a day af­ter the fast-sell­ing GIP/GLP-1 re­cep­tor ag­o­nist was ap­proved in the US for the same in­di­ca­tion. It’s known as Moun­jaro in type 2 di­a­betes, but it will be mar­ket­ed in the US for weight man­age­ment as Zep­bound.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.